James Mitchum
Chief Executive Officer chez Regalorx
Profil
James P.
Mitchum is currently the Chief Executive Officer at Regalorx since 2019 and the Director at Heart to Heart International, Inc. since 2014.
Previously, he served as the Chief Executive Officer at Aventis Pharma UK from 2000 to 2002, President & Chief Executive Officer at Enturia, Inc. from 2005 to 2008, President & Chief Executive Officer at Sanofi-Aventis Japan from 2003 to 2005, and Independent Director at Tenax Therapeutics, Inc. from 2015 to 2021.
He also held the position of Independent Director at Medpace Research, Inc. from 2013 to 2017.
Additionally, he worked as the Controller at HMR Pharma, Inc. from 1997 to 2000 and as the President & Chief Operating Officer at Medi-Flex Ltd.
He served as the President-Americas Region at EUSA Pharma, Inc. from 2009 to 2012 and as the Controller at Hoechst Marion Roussel, Inc. from 1985 to 2000.
Mr. Mitchum completed his undergraduate degree at Milligan College and holds an MBA from the University of Tennessee.
Postes actifs de James Mitchum
| Sociétés | Poste | Début |
|---|---|---|
Heart to Heart International, Inc.
 Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | Director/Board Member | 02/09/2014 |
| Regalorx | Chief Executive Officer | 01/01/2019 |
Anciens postes connus de James Mitchum
| Sociétés | Poste | Fin |
|---|---|---|
| TENAX THERAPEUTICS, INC. | Director/Board Member | 08/09/2021 |
| NEPHROGENEX INC | Director/Board Member | 01/01/2017 |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Corporate Officer/Principal | 01/07/2012 |
Enturia, Inc.
 Enturia, Inc. Medical SpecialtiesHealth Technology Enturia, Inc. develops and manufactures medical devices and drugs. Its products include Swabstick 1.75mL, Sepp 0.67mL and Frepp1.5mL. The company research and develops products which cures human health diseases. Enturia was founded by Joseph A. Brandmeyer in 1985 and is headquartered in Leawood, KS. | Chief Executive Officer | 01/01/2008 |
| Sanofi-Aventis Japan | Chief Executive Officer | 01/01/2005 |
Formation de James Mitchum
| Milligan College | Undergraduate Degree |
| University of Tennessee | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TENAX THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
| HMR Pharma, Inc. | |
Medi-Flex Ltd.
 Medi-Flex Ltd. Financial ConglomeratesFinance Medi-Flex Ltd. operates as an investment holding company, which engages in the manufacturing and trading of rubber gloves. It offers clean room loves, nitrile examination gloves, prepowdered & powder free latex examination gloves, medical examination and industrial gloves for the semiconductor, healthcare and a wide range of industrial applications markets. The company was founded in April 1999 and is headquartered in Singapore. | Finance |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Health Technology |
| Aventis Pharma UK | |
Medpace Research, Inc.
 Medpace Research, Inc. Medical DistributorsDistribution Services Medpace Research, Inc. is a pharmaceutical company, which focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. The company was founded by Billy G. Hudson, J. Wesley Fox Ahmann and Tryggvason Karl on May 25, 2004 and is headquartered in Cincinnati, OH. | Distribution Services |
Enturia, Inc.
Enturia, Inc. Medical SpecialtiesHealth Technology Enturia, Inc. develops and manufactures medical devices and drugs. Its products include Swabstick 1.75mL, Sepp 0.67mL and Frepp1.5mL. The company research and develops products which cures human health diseases. Enturia was founded by Joseph A. Brandmeyer in 1985 and is headquartered in Leawood, KS. | Health Technology |
| Hoechst Marion Roussel, Inc. | |
| Sanofi-Aventis Japan | |
Heart to Heart International, Inc.
Heart to Heart International, Inc. Miscellaneous Commercial ServicesCommercial Services Heart to Heart International, Inc. develops humanitarian programs that promote health and wellness. It responds to health crises and natural disasters. The company was founded by Gary Morsch and James Kerr in 1992 and is headquartered in Lenexa, KS. | Commercial Services |
| Regalorx |
